defined the PRMT3‐IGF2BP1‐HEG1 axis as an important regulatory factor and therapeutic target for oxaliplatin resistance, indicating the potential of using PRMT3 expression levels as a biomarker for oxaliplatin resistance in HCC patients based on pre‐treatment biopsies [43]. The gene discussed is PRMT3; the disease is hepatocellular carcinoma.